INmune Bio Inc Cash Flow-to-Debt Ratio
INmune Bio Inc cash flow-to-debt ratio. INmune Bio Inc (INMB) has a Cash Flow-to-Debt Ratio of -1.01x as of June 2026, meaning its operating cash flow of $-6.58 Million could theoretically repay -1% of its total liabilities ($6.48 Million) in one year. Check INMB cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of INmune Bio Inc (2015–2025)
Cash flow-to-debt ratio of INmune Bio Inc from 2015 to 2025. Historical debt coverage capacity for INmune Bio Inc across 11 annual periods. Also explore net asset momentum of INmune Bio Inc to track the company's year-over-year net asset growth rate.
INmune Bio Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
INmune Bio Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for INmune Bio Inc. For the full cash flow conversion analysis, see INmune Bio Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.56x | $-22.58 Million | $8.83 Million | ▲ +42.8% |
| 2024 | -4.47x | $-33.36 Million | $7.46 Million | ▼ -603.6% |
| 2023 | -0.64x | $-11.98 Million | $18.86 Million | ▲ +39.3% |
| 2022 | -1.05x | $-22.69 Million | $21.69 Million | ▲ +27.6% |
| 2021 | -1.45x | $-28.50 Million | $19.72 Million | ▲ +69.3% |
| 2020 | -4.70x | $-8.94 Million | $1.90 Million | ▲ +24.9% |
| 2019 | -6.26x | $-5.38 Million | $860.54K | ▼ -150.3% |
| 2018 | -2.50x | $-2.06 Million | $823.77K | ▼ -1.6% |
| 2017 | -2.46x | $-761.83K | $309.72K | ▼ -365.6% |
| 2016 | -0.53x | $-317.38K | $600.81K | ▲ +10.3% |
| 2015 | -0.59x | $-18.12K | $30.75K | — |